Published in final edited form as:

Bioconjug Chem. 2013 April 17; 24(4): 658–668. doi:10.1021/bc300632w.

Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for targeting of CD44-positive and drug-resistant tumors

Xin Wei, Thulani H. Senanayake, Galya Warren, and Serguei V. Vinogradov*

Center for Drug Delivery and Nanomedicine and Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198-6025, United States

Abstract

Many drug-resistant tumors and cancer stem cells (CSC) express elevated levels of CD44 receptor, a cellular glycoprotein binding hyaluronic acid (HA). Here, we report the synthesis of nanogel-drug conjugates based on membranotropic cholesteryl-HA (CHA) for efficient targeting and suppression of drug-resistant tumors. These conjugates significantly increased the bioavailability of poorly soluble drugs with previously reported activity against CSC, such as etoposide, salinomycin, and curcumin. The small nanogel particles (diam. 20–40 nm) with a hydrophobic core and high drug loads (up to 20%) formed after ultrasonication and demonstrated a sustained drug release following the hydrolysis of biodegradable ester linkage. Importantly, CHA-drug nanogels demonstrated 2–7 times higher cytotoxicity in CD44-expressing drug-resistant human breast and pancreatic adenocarcinoma cells compared to free drugs and non-modified HA-drug conjugates. These nanogels were efficiently internalized via CD44 receptor-mediated endocytosis and simultaneous interaction with the cancer cell membrane. Anchoring by cholesterol moieties in the cellular membrane after nanogel unfolding evidently caused more efficient drug accumulation in cancer cells compared to non-modified HA-drug conjugates. CHA-drug nanogels were able to penetrate multicellular cancer spheroids and displayed higher cytotoxic effect in the system modeling tumor environment than both free drugs and HA-drug conjugates. In conclusion, the proposed design of nanogel-drug conjugates allowed us to significantly enhance drug bioavailability, cancer cell targeting, and the treatment efficacy against drug-resistant cancer cells and multicellular spheroids.

Keywords

nanogel; hyaluronic acid; CD44; drug conjugate; cancer spheroids; drug-resistant cancer cells

Introduction

Most current therapeutic strategies are unable to completely eliminate tumors and to overcome the emerging resistance to many anti-cancer drugs and tumor relapse, providing only palliative solutions to cancer patients. The development of drug resistance and tumor

*Corresponding Author: 986025 Nebraska Medical Center, Omaha, NE 68198-6025. Phone: (402) 559-9362; Fax: (402) 559-9543; vinograd@unmc.edu.

The authors declare no competing financial interest.

Supporting information. Characterization data for HA-drug conjugates were summarized in Table 1. ¹H-NMR spectra of CHA-ETO, CHA-SAL and CHA-CUR were provided in Figure 1–3, respectively. This information is available free of charge via the Internet at <http://pubs.acs.org/>

relapse have been closely associated recently with the accumulation of cancer-initiating or cancer stem cells (CSCs) in tumors following chemotherapy (1). These CSCs are characterized by overexpression of drug efflux transporters, formation of multicellular spheroids, and overall reduced metabolic activity, which make them resistant to cytotoxic drugs (2). Drug combination therapies, immunotherapies, and nanoformulated drugs were found effective in order to circumvent the drug resistance (3). Nanodelivery can also improve solubility of many low soluble drugs, increase drug accumulation in tumors, and decrease cytotoxic side effects. Although, a significant progress was made in the development of nanodelivery, even the most advanced drug delivery systems such as liposomes and polymer micelles are far from optimal; for example, encapsulated drugs can rapidly diffuse through liposome bilayer, while micellar drugs often demonstrated *in vivo* instability, and both systems sometimes had drug loading capacity too low to produce therapeutic effect (4, 5). Prodrug approaches using polymeric drug conjugates look more attractive because of the higher drug loading capacity and controlled drug release depending on the drug-linker stability (6). We recently reported the synthesis of cholesteryl nanogel-drug conjugates that contained biodegradable tetraphosphate linker and could deliver cytotoxic nucleoside analogues in activated phosphorylated form (7). These polyvinyl alcohol or dextrin-based nanogel-drug conjugates demonstrated excellent activity against many resistant to nucleoside analogs cancer cells. In this paper, we extend this successful nanogel design to the preparation of biodegradable hyaluronic acid-drug conjugates that could be applied to the treatment of CD44-positive drug-resistant cancer cells and, potentially, CSCs.

Hyaluronic acid (HA) is a linear anionic polymer composed of repeating disaccharide units of β -1,4-D-glucuronic acid- β -1,3-N-acetyl-D-glucosamine. HA with different MWs play different roles in the body. Low-MW polymer typically induces receptor-mediated intracellular signaling, while high MW-polymer maintains cell integrity and matrix organization (8). This biocompatible, biodegradable and non-immunogenic biomaterial has been extensively studied in pharmaceutical and biomedical applications, including cancer therapy, when various drugs have been conjugated to HA, like paclitaxel or doxorubicin (9–11). Many drug-resistant cancer cells and CSCs display elevated levels of CD44 receptor that binds HA (12). Potentially, CD44 can be targeted for the treatment of drug-resistant tumors and CSCs (35). Previously, it was shown that HA-grafted liposomes have an increased cellular uptake through CD44-mediated endocytosis, which is a highly regulated process of binding, internalization, and the ligand transfer through a series of intracellular compartments (13,14).

Hydrophobic modification of polymer prodrugs can improve the internalization of nanocarriers through interaction with cellular membrane. Modification with cholesterol, which is a common component of cellular membrane, resulted in significant improvement of cellular accumulation of various macromolecules (e.g. siRNA) and polymers for drug delivery applications (18,19). The presence of hydrophobic moieties was also helpful in preparation of compact polymeric nanoparticles or nanogels after ultrasonication of modified polymers in water. For example, nanoparticles formed from ceramide-modified HA (HACE) have been recently introduced as drug carriers and bioimaging probes (15–17). Here, our goal was to assemble nanocarriers, which could deliver drugs more efficiently than simple HA-drug conjugates, and apply them to the treatment of drug-resistant cancer cells, spheroids and, potentially, CSC. For this purpose, we designed and evaluated novel compact nanogels based on cholesterol-modified HA (CHA) that could be conjugated via biodegradable covalent linkage with selected drugs previously found highly active against CSCs.

A high throughput drug screening study identified several drug candidates for the treatment of CSCs, like etoposide (ETO) and salinomycin (SAL) (20). Salinomycin, a veterinary antibiotic, displayed 100 times higher efficacy against CSCs than paclitaxel. The major shortcoming of salinomycin was its toxicity that did not allow the drug application for human patients. Etoposide, a topoisomerase inhibitor and popular anticancer drug, was only a little less active than salinomycin. Toxicity profile of etoposide as anticancer drug was far from optimal, demonstrating hematologic and gastrointestinal toxicity. Novel potential anticancer drug, curcumin (CUR), demonstrated efficacy against multiple cancer targets and was also found very effective against CSCs (21). However, low stability and poor bioavailability of curcumin reduce its value as a drug.

Here, we designed nanogel-drug conjugates that are free of many of these shortcomings. All these drugs (ETO, SAL and CUR) contain hydroxyl groups in chemical structure, which form biodegradable esters after chemical conjugation with carboxyl groups of HA. The CHA-drug conjugates form compact stable nanogels due to the intramolecular folding of HA strands and the formation of hydrophobic core after ultrasonication in aqueous solution. These nanogels could effectively target CD44 receptors on drug-resistant cancer cells. Evidently, these nanogels could unfold on cellular membrane anchoring in lipid bilayer by multiple cholesterol moieties. This process may lead to the formation of semipermeable patches in the cellular membrane and results in the efficient cytoplasmic drug release, and the eventual inhibition of cancer cell growth.

Materials and methods

Materials

Most reagents and solvents were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise indicated. 5-fluoro-2'-deoxyuridine (Floxuridine, FdU) was from SynQuest Laboratories (Alachua, FL). Dialysis tubing (MWCO, 12–14 kDa) was purchased from Fisher Scientific (Pittsburgh, PA). The silicagel for column chromatography was from Whatman (GE Healthcare, USA). Etoposide was purchased from Ochem (Des Plaines, IL). Salinomycin was purchased from Chemieliva Pharmaceutical (Chongqing, China). Hyaluronic acid sodium salt (MW 62 kDa) was purchased from Quingao Biomedical (Chaska, China).

Cell lines

Human breast carcinoma cell lines MDA-MB-231 and MCF-7 were obtained from ATCC (Rockville, MD). Human pancreatic cancer MIA PaCa-2 cells were a kind gift from Dr. Surinder K. Batra (Eppley Cancer Institute, UNMC). MCF-7 and MIA PaCa-2 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM, HyClone/ThermoScientific) supplemented with 10% fetal bovine serum (FBS), 1% L-glutamate, 2% penicillin/streptomycin. MDA-MB-231 cells were grown in DMEM/Nutrient mixture F-12 (DMEM/F12, HyClone/ThermoScientific) with the same additives. Drug-resistant MDA-MB-231/F cells were selected by the routine exposure to the increasing doses of floxuridine over the period of 6 months. The resistant cell line was cultured in the same growth medium containing 10 µg/mL floxuridine to maintain the drug-resistant phenotype. All cells were cultured at 37°C in humidified atmosphere with 5% CO₂.

Synthesis of cholesteryl-hyaluronic acid (CHA)

Aqueous solution of HA (sodium salt) was passed through a column with Dowex 50×8 (H⁺-form) and lyophilized. A solution of 2,2'-(ethylenedioxy)-bis-ethylamine linker (L) (5 g, 30 mmol) in 30 mL anhydrous dichloromethane (DCM) containing 0.75 g (7.5 mmol) of triethylamine was used in reaction with cholesteryl chloroformate (CC) (3.36 g, 7.5 mmol)

dissolved in 20 mL of DCM and added dropwise over 30 min under argon. The final mixture was stirred overnight at 25°C, filtered and concentrated *in vacuo*. The cholesteryl-amine linker was isolated following the column chromatography on silica gel using a stepwise methanol gradient (6, 9, 12 and 15%) in DCM with a yield of 76%.

Cholesteryl-HA (CHA) was synthesized by activation of HA (4 g, 10 mmol carboxyl groups) dried by co-evaporation with toluene *in vacuo* and dissolved in 100 mL of warm anhydrous dimethyl sulfoxide (DMSO) using 100 mg (0.64 mmol) of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), 90 mg (0.64 mmol) of hydroxybenzotriazole (HOBT), 80 μ L of TEA and 10 mg of 4-dimethylaminopyridine (DMAP) at continuous stirring under argon. After 4 h-reaction at 25°C, a cholesteryl-amine linker (384 mg, 0.64 mmol) dissolved in 10 mL DMSO was added, and the reaction mixture was stirred for 2 days at 25°C. The product (CHA) was dialyzed in semipermeable tubes (MWCO 12–14 kDa) against water three times for 24 hours at 25°C and then concentrated *in vacuo*. CHA was dissolved in small volume of methanol and purified by gel filtration on Sephadex LH-20 column, using methanol as an eluent, with an yield of 85% after concentration *in vacuo*.

Synthesis of drug conjugates

CHA (100 mg, 0.25 mmol carboxyl groups) was dried by co-evaporation with anhydrous toluene *in vacuo* and dissolved in 5 mL anhydrous DMSO containing 42 μ L (0.25 mmol) N,N-diisopropylethylamine (DIPEA). Separately, 44 mg (0.075 mmol) of etoposide (ETO), or 56 mg of salinomycin (SAL), or 28 mg of curcumin (CUR) were dried with 2 mg of DMAP by co-evaporation with anhydrous toluene *in vacuo* and mixed with the CHA solution at the drug to CHA molar ratio 30:1. Then, N,N-dicyclohexylcarbodiimide (DCC, 16 mg, 0.075 mmol) in 0.5 mL of anhydrous DMSO was added, and the reaction mixture was stirred for 3 days at 25°C under argon. Water (10 μ L) was added to stop the reaction, and the mixture was left overnight at 4°C. The solution was filtered, dialyzed against water (MWCO 12–14 kDa) and concentrated *in vacuo*. CHA–drug conjugates were isolated by gel filtration on Sephadex LH-20 column in methanol as an eluent. When dissolved in water, pH of CHA-drug conjugates was adjusted to 7, and, finally, they were dialyzed against water overnight at 4°C and lyophilized with a yield of 65–75%. The same procedure was used for the synthesis of non-modified HA-drug conjugates.

Synthesis of Rhodamine-labeled HA and CHA-drug conjugates

100 mg of HA- or CHA-drug conjugate was dissolved in DMSO containing 2 mg EDC, 2 mg HOBT, 20 μ L TEA and 2 mg DMAP and the reaction mixture was stirred for 4 h at 40°C. Then 10 mg of 2,2'-(ethylenedioxy)-bis-ethylamine linker (L) was added, and the reaction was continued for 2 h at 25°C. The product was dialyzed against water overnight, concentrated *in vacuo*, and the pH of the solution was adjusted to 8 by carbonate buffer. Rhodamine B isothiocyanate (3 mg) was dissolved in 50% aqueous dimethylformamide (DMF) and added to the above solution, and the reaction mixture was stirred overnight at 25°C. Rhodamine-labeled Rh-HA or Rh-CHA-drug conjugates were dialyzed against water for 2 days at 4°C and lyophilized.

Characterization of CHA-drug conjugates

Quantitative analysis of the cholesterol and drug content was performed by using ^1H -NMR spectroscopy. ^1H -NMR spectra were recorded in d-DMSO at 25°C using a 500 MHz Varian NMR spectrometer. All chemical shift values are given in parts per million (ppm) and are referenced to a signal from tetramethylsilane. The ^1H -NMR spectrum of CHA-ETO contained signals (see Supporting Information, Figure 1): 0.65 (s, 36H), 0.835–1.66 (m, 336H), 1.8 (m, 459H), 3.06–3.54 (m, 1925H), 4.05–4.08 (m, 22H), 4.23–5.22 (m, 963H),

6.01–6.03 (d, $J=10$ Hz, 44H), 6.17 (s, 44H), 6.52 (s, 22H), 6.99 (s, 22H). The integrated signals for cholesterol methyl group (0.65 ppm), *N*-acetyl group of HA (1.8 ppm) and aromatic ring of etoposide (6.17 ppm) have been selected for the calculation of cholesterol and ETO content. The ^1H -NMR spectrum of CHA-SAL contained signals (see Supporting Information, Figure 2): 0.65–1.64 (m, 454H), 1.84 (m, 459H), 3.00–3.94 (m, 1844H), 4.42–4.97 (m, 765H), 5.89 (d, $J=11$ Hz, 23H), 6.15 (d, $J=10.5$, 23H). The integrated signals for *N*-acetyl group of HA (1.84 ppm) and tetrahydropyranyl ring of salinomycin (5.89 ppm, 6.15 ppm) have been selected for SAL content calculation. The ^1H -NMR spectrum of CHA-CUR (see Supporting Information, Figure 3): 0.65–1.66 (m, 264H), 1.80 (m, 459H), 3.00–3.83 (m, 1997 H), 4.10–5.12 (m, 963 H), 5.32 (6H), 6.05 (s, 12H), 6.73 (d, $J=16$ Hz, 2H), 6.83 (d, $J=8$ Hz, 2H), 7.15 (d, 8 Hz, 12 H), 7.318 (s, 12 H), 7.557 (d, $J=16$ Hz, 12H). The integrated signals for *N*-acetyl group of HA (1.8 ppm) and aromatic ring of curcumin (7.15 ppm) have been selected for CUR content calculation.

These CHA-drug conjugates formed compact nanogels after ultrasonication in aqueous solution. Usually, 30 min treatment in bath sonicator was sufficient to obtain small uniform particles. The particle size, polydispersity and zeta-potential of these nanogels were measured by dynamic light scattering (DLS) using a Zetasizer Nano-ZS90 (Malvern Instruments, Southborough, MA) with a 15 mV solid state laser operated at a wavelength of 635 nm. The morphology and diameter of nanogel particles were also determined by transmission electron microscopy (TEM) after contrast staining with vanadate using a FEI Tecnai G2 Spirit instrument.

***In vitro* drug release and stability study**

In vitro drug release was performed as follows. Solutions of CHA-drug nanogels (10 mg in 1 mL) were placed in small dialysis tubes (MWCO 3k) and immersed in 50 mL of PBS (pH 7.4) containing 0.1% sodium azide. During incubation at 25°C under slow stirring, 100 μL samples were withdrawn from the PBS buffer at selected time points, and their UV absorbance was measured at 280 nm in triplicate using NanoDrop (ThermoScientific, Waltham, MA). Serial dilutions of drugs have been measured at 280 nm to obtain standard curves used to calculate the amount of drug released from nanogel. Data were expressed in the form of cumulative drug release vs. incubation time.

Degradation of curcumin can be detected by the significant reduction of its absorbance at λ_{max} 426 nm. In curcumin stability studies, CHA-CUR nanogel (2 mg/mL) and CUR solutions in PBS, pH 7.4, were incubated at 25°C. At selected time points, UV spectra have been measured using a SpectraMax M2 Microplate Reader (Molecular Devices, USA).

***In vitro* cytotoxicity assays**

Cytotoxicity of CHA- and HA-drug conjugates and free drugs was determined in cancer cell lines using a standard MTT assay. Briefly, 100 μL of cell suspension was seeded in flat-bottom 96-well plates at a density of 5 000 cells/well. Cells were allowed to attach at 37°C overnight, and then 100 μL of sample solutions at serial dilutions in full medium were added. Cells were incubated for 72 h at 37°C, and metabolic activity of samples was determined by adding 20 μL of MTT solution (5 mg/mL) in sterile PBS to each well. Plates were incubated for 4 h at 37°C and centrifuged (500 $\times$ g, 5 mins) to remove medium. Then, 100 μL of extraction buffer (20% w/v SDS in 50% DMF, pH 4.7) was added to each well. Samples were incubated for 24 h at 37°C. Optical absorbance at 560 nm was measured using a Model 680 microplate reader (BioRad, Hercules, CA). All cytotoxicity data were obtained from parallel sample measurements ($n = 8$) and plotted as survival percentage compared to control non-treated cells vs. drug/nanogel concentrations. Data were converted into IC_{50} values (concentration of the 50% cell survival).

The lactate dehydrogenase (LDH) assay kit II (BioVision, San Diego, CA) was used to evaluate cytotoxicity of nanogels in tumor spheroids according to manufacturer's instructions. In brief, cancer cell spheroids were treated in 96-well plate with free drug, HA-drug conjugates and CHA-drug nanogel. Two rows of control non-treated cells were set up. In 'low' control, no cell lysis buffer was used. In 'high' control, cells were treated with 10 μ L of cell lysis buffer per well for 15 min. Cells were precipitated by centrifugation, and culture medium was collected and treated with LDH Reaction Mix solution for 30 min at 25°C. After the absorbance of controls and samples was measured at 450 nm, cytotoxicity as a percentage of dead cells was calculated using the following equation:

$$\text{Cytotoxicity (\%)} = (\text{sample} - \text{'low' control}) / (\text{'high' control} - \text{'low' control}) \times 100$$

Flow cytometry

CD44 expression levels in MDA-MB-231/F, MCF-7 and MIA PaCa-2 cells were determined using an allophycocyanin (APC)-conjugated mouse anti-human CD44 antibody (BD Pharmingen). Cells were washed once with PBS and then harvested with 0.05% trypsin/0.025% EDTA. Detached cells were washed and resuspended in wash buffer containing PBS, 1% FBS and 1% penicillin/streptomycin (10^6 cells/100 μ L). Fluorochrome-conjugated monoclonal antibody against human CD44 was added to the cell suspension at concentration recommended by the manufacturer and incubated at 4°C in the dark for 30 min. The antibody-labelled cells were washed in the wash buffer and fixed in PBS containing 1% paraformaldehyde, and then analyzed by flow cytometry on a FACS Vantage (BD Biosciences).

Cellular uptake

In cellular uptake experiments, cells were seeded in black-walled plates, and Rhodamine-labeled conjugates were added at different concentrations in triplicates. Plates were incubated at 37°C for 2 h, washed 3 times with ice cold PBS, and treated with cell lysis buffer for 10 min. Fluorescence in the samples was measured using a BioTek FLx-800 fluorescence plate reader. Similar procedure was performed in time-dependence studies, where Rhodamine-labeled conjugates (50 μ g per well) were used in cell treatment, and cell samples were obtained at different time points in triplicates.

In order to investigate whether the uptake of CHA conjugates was a CD44-dependent endocytosis, we carried out energy depletion and competitive inhibition studies. In the energy depletion study, cells were incubated at 4°C and 37°C. The Rh-CHA uptake was measured as described above. In the competitive inhibition study, cells were pretreated with free HA (2 mg/mL, pH 7.4) for 1 h, washed and treated with Rh-CHA (50 μ g per well) in quadruplicates for 2 h at 37°C. The uptake was compared with that of cells without pretreatment. Similarly was measured the uptake of free carriers HA and CHA without drugs.

The uptake in living cell was visualized under each condition by confocal microscopy using Zeiss 510 Meta Confocal Laser Scanning Microscope.

Multicellular cancer spheroids (MCS)

To prepare plates for cultivation of MCS, we used the following protocol (33). 1 g of poly(2-hydroxyethyl methacrylate) (poly-HEMA) was dissolved in 50 mL 95% ethanol overnight. The solution was clarified by centrifugation (2,000 g, 10 min) and applied in 96-well U-bottom culture plates (50 μ L per well). The plates were dried overnight in sterile hood under UV light, rinsed with PBS, and used for cultivation of MCS. In all assays, the

spheroids were formed 2 days after inoculation and maintained in complete MammoCult™ Medium (StemCell Technology, USA) including 0.0004% of heparin and 1 μM of hydrocortisone. These spheroids were cultured to the size 200–400 μm before at living cell conditions studies. Penetration of Rh-CHA-ETO in spheroids was monitored by confocal laser scanning microscopy. For cytotoxicity studies, spheroids were incubated with CHA-ETO and then treated as described above.

Statistical analysis

Statistical analysis was performed by application of the two-tailed unpaired Student t-test using SPSS 16.0 software. Differences between groups were considered significant at $P < 0.05$.

Results and discussion

Synthesis and characterization of HA-based drug conjugates

We synthesized cholesteryl-hyaluronic acid-drug conjugates as shown in Scheme 1A. It was earlier determined that CD44-binding efficacy of HA depends on its Mw, and the stable binding occurs with HA having a Mw of at least 30 kDa (23). Here, we chose the HA with Mw of 60 kDa in order to obtain smaller nanogels with sufficient drug-loading capability and good CD44-binding efficacy. Following the modification with cholesterol, amphiphilic CHA conjugates could form compact nanogels (<100 nm in diameter) after ultrasonication in aqueous media. Previously, we observed that the degree of modification of hydrophilic cationic nanogels with cholesterol chloroformate must be between 3 and 10% in order to ensure good solubility and effective cellular uptake of cholesteryl-nanogels (24). Here, we used a cholesteryl-amine linker (L) synthesized from 2,2'-(ethylenedioxy)-bis-ethylamine in order to obtain stable CHA nanogel (Scheme 2A). This linker was used for modification of carbodiimide-activated carboxyl groups in a 6-fold molar excess over HA molecule. ¹H-NMR analysis confirmed the high reaction efficacy: the cholesterol content in CHA was equal to 3.5±0.3% or 5.9 cholesterol molecules in average per HA polymer. It was in good correlation with the input amount of the cholesteryl-amine linker used in the synthesis (Table 1).

In the second step, the CHA nanogel was covalently conjugated to etoposide, salinomycin, or curcumin through the formation of degradable ester bonds. As shown in Scheme 1B, carboxyl groups of CHA were activated by dicyclohexylcarbodiimide (DCC) and coupled with above-mentioned drugs in anhydrous conditions (25). The final drug content in conjugates directly depended on the input amount of drug used in the coupling (Table 1). The CHA-drug nanogels could be obtained with higher drug loading compared to many liposomal drug formulations (7–11%) (7, 14). We demonstrated that drug solubility could be elevated by at least 100 times when CHA-drug nanogels are used.

Nanogel formation

The synthesized CHA-drug conjugates readily formed compact nanogels after ultrasonication in aqueous media. Usually, 30–60 min treatment in bath sonicator (70W, 42 kHz±6%) was sufficient to obtain uniform nanogel particles mostly free of aggregates. Particle size, polydispersity, and morphology of nanogels were investigated by dynamic light scattering and transmission electron microscopy (Table 1, Figure 1). All three nanogel-drug conjugates formed small particles with a spherical morphology, narrow size distribution, and hydrodynamic diameters between 29 and 40 nm. HA-drug conjugates formed much larger particles (see Supporting Information Table 1). Zeta-potential of all nanogels was negative (Table 1) due to the high amount of carboxyl groups in HA. Compared to HA-grafted liposomes having a diameter 120–180 nm (14) or HACE

nanoparticles with particle sizes more than 100 nm (16, 17), CHA-drug nanogels have significantly lower particle sizes. For the efficient accumulation in tumor tissue via enhanced permeability and retention (EPR) effect, nanocarriers should be smaller than 200 nm, since nanocarriers larger than 200 nm are predominantly cleared by the reticuloendothelial system (RES) (26). The smaller size is prerequisite for the efficient penetration of nanocarriers into tumor mass, as well as their transport through gastrointestinal barrier where absorption of nanoparticles was 15–250 times than microparticles (36).

***In vitro* drug release and stability**

The *in vitro* drug release from CHA-drug nanogels was monitored at 37°C and pH 7.4 in order to assess nanogel stability in physiological condition. Both CHA-ETO and CHA-SAL nanogels showed practically identical slow release profiles with a mean release rate of 1.6–1.7% per day (Figure 2A). Since the major problems of therapeutic curcumin are its low solubility and rapid degradation in physiological conditions (27), we monitored the drug stability in CHA-CUR nanogel by the drop in absorbance at 430 nm (Figure 2B). UV spectrum of CHA-CUR solution showed less than 10% drug degradation after 24 h-incubation at pH 7.4. In the same conditions, most of free curcumin was degraded during that time (Figure 2C). It was earlier demonstrated that esterification of curcumin significantly increase its stability to oxidation in neutral conditions (37).

Cytotoxicity

We compared cytotoxicity of CHA-drug nanogels, HA-drug conjugates and free drugs in drug-resistant human breast carcinoma MDA-MB-231/F (selected by resistance to floxuridine) and pancreatic adenocarcinoma MIA PaCa-2 (medium gemcitabine-resistant) cells using a thiazolyl blue (MTT)-based cytotoxicity assay (Figure 3). CHA-drug nanogels demonstrated lower IC₅₀ values compared to both free drugs and HA-drug conjugates as shown in Table 2. We calculated the enhancement factor (EF), which is defined as IC₅₀ (drug)/IC₅₀ (drug formulation). The EF values of CHA-ETO, CHA-SAL and CHA-CUR were equal to 4.2, 5.4 and 2.1, respectively. Furthermore, the cytotoxicity of CHA-ETO, CHA-SAL and CHA-CUR nanogels was also 2.1, 3.4 and 7.8 times higher compared to HA-ETO, HA-SAL and HA-CUR conjugates, respectively. Meanwhile, the CHA empty nanogel demonstrated a negligible cytotoxicity (IC₅₀ > 5 mg/mL). Thus, application of CHA nanogels not only improved particle size, but also significantly enhanced the anticancer efficacy of conjugated drugs.

Intracellular uptake

Cellular accumulation of HA is driven by energy-dependent CD44 receptor-mediated endocytosis, although the mechanism of it is not yet fully understood (28). Here, we evaluated effects of cholesterol substitution on the cellular uptake of Rhodamine-labeled CHA nanogel in cancer cells expressing different levels of CD44. Analysis of CD44 expression by flow cytometry demonstrated that human breast carcinoma MCF-7 cells expressed the lowest CD44 level, while MDA-MB-231/F and MIA PaCa-2 demonstrated 15 times and 29 times higher CD44 levels, respectively (Fig. 4B). Confocal microscopy showed an active nanogel accumulation in MDA-MB-231/F cells at 37°C that was significantly suppressed at 4°C (Fig. 4A,a-b). A 40% decline in accumulation was confirmed by direct measurements of fluorescence normalized for the same amount of cells (Fig. 4C,a). Thus, cellular uptake of CHA nanogels was, at least partly, an energy-dependent process of receptor-mediated endocytosis. Pre-treatment of cells with free HA also resulted in the partial inhibition of CHA nanogel accumulation which supports the direct involvement of the receptor-mediated mechanism of uptake (Fig. 4A,c and 4C,b). Direct comparison of Rhodamine-labeled HA and CHA showed that the uptake of CHA nanogel was at least 20%

more efficient (Fig. 4A,d and 4C,c). Evidently, interaction of cholesterol moieties with the cellular membrane plays a prominent role in cellular internalization of CHA nanogels. Reduced level of CHA nanogel accumulation was observed in MCF-7 cells that expressed significantly lower CD44 levels compared to MDA-MB-231/F (Fig. 4A,e and 4C,d).

Vectorized nanocarriers are internalized mostly by receptor-mediated endocytosis. Endosome-sequestered nanocarriers are then transferred into lysosomes, where they are digested and have their cargos degraded, and the remains are finally recycled out of cells (28). Acid labile linkers (hydrazone, ester groups) are usually introduced in prodrugs to facilitate intracellular drug release, since late endosomes and lysosomes have pH in the range 5.0–5.5 (29). Hydrophilic prodrugs like HA-drug conjugates may remain in the endosome and degrade or recycle later. In contrast, the CHA-drug nanogels provide strong advantage in more effective drug delivery since they can easily unfold on the membrane surface after the receptor-mediated endocytosis by anchoring in the lipid bilayer via multiple cholesterol moieties. Thus, superior cytotoxic efficacy of CHA-drug conjugates compared to HA-drug conjugates in cancer cells can be explained by this ability to fuse with the cellular membrane and form semi-permeable patches allowing fast drug release in cytoplasm as shown in Scheme 2. Similar mechanism of drug release including the fusion with the cellular membrane was previously identified for cationic nanogels that delivered hydrophilic drugs otherwise incapable to penetrate the lipid bilayer (30). The main location of CD44 receptor is on lipid rafts that are rich in cholesterol as a previous report suggested (31). Potentially, both interactions with lipid rafts and CD44 receptors could work in concert for CHA nanogels to enhance the intracellular drug delivery. Our results show that the accumulation of CHA nanogels is a process where nearly equal parts are determined by CD44-mediated endocytosis and the cholesterol-related interaction with the membrane of cancer cells. The CHA accumulation levels correlated well with the CD44 expression in different cell lines. Accumulation of HA-engrafted liposomes and HACE-based nanoparticles was also CD44-dependent (14, 16). Thus, the direct comparison of HA polymer and CHA nanogels demonstrated that cholesterol modification is the major factor in the observed higher cellular accumulation of CHA nanogels and stronger cytotoxicity of CHA nanogel-drug conjugates.

Penetration and cytotoxicity of CHA nanogels in cancer spheroids

3D-culture of multicellular cancer spheroids (MCS) was proposed as better model for drug efficacy testing than cellular monolayers since the MCS cultures share many properties of solid tumors, such as the development of extracellular matrix (ECM), nutritional concentration gradients, and the outer layer-to-core cell proliferation (32). MCS may consist of a proliferating, quiescent and necrotic core regions and form oxygen and glucose gradients similar to solid tumors. MCS models also demonstrated higher drug resistance and tumor-like penetration of therapeutic molecules as compared to cellular monolayers. Many hydrophobic drugs are bound only to outer layers of MCS, which results in poor drug transport into inner parts of MCS. Obviously, encapsulation of hydrophobic drugs in hydrophilic nanocarriers can make the process more efficient.

Here, we examined the penetration and cytotoxic activity of CHA-drug nanogels in 3D-cultures of MCF-7 and MIA PaCa-2 MCS. The spheroids were grown for several days to the size of 300–400 μm in low adhesion plates and at low-serum conditions (33). After supplementing the MCS with full medium, they were incubated with Rhodamine-labeled CHA-ETO and CHA-SAL. As shown by confocal microscopy, both nanogel-drug conjugates could penetrate MCF-7 MCS by 50–60 μm after 12h-incubation (white arrow), a penetration rate equal to 4–5 μm per hour (Fig. 5A, B). An average area of MCF-7 cells is 400 μm^2 or 20 $\times$ 20 μm . Thus, nanogel can penetrate through up to 6 cell layers per day. For most MCS, it would take approximately three days for CHA nanogel-drug conjugates to

penetrate in the core. Along with the penetration, CHA nanogels could bind CD44 receptors and rapidly internalize into cancer cells and kill them (Fig. 5C). Their very small size was positive factor enhancing the CHA nanogel-drug efficacy; previous experiments with larger nanocarriers demonstrated very slow penetration (34).

To compare cytotoxicity of CHA-ETO and HA-ETO, we measured extracellular release of lactate dehydrogenase (LDH) caused by the rupture of cellular membrane in apoptotic and dead cells following 48h-treatment of MIA PaCa-2 MCS. Cytotoxicity was expressed as a percentage of dead cells in the total MCS cell amount. The cytotoxicity of free ETO and CHA-ETO was mostly equal and significantly higher than cytotoxicity of HA-ETO at all drug doses. CHA-ETO demonstrated 2-fold and 4-fold better cytotoxic effect against MCS compared to ETO and HA-ETO, respectively, at a higher dose (Fig. 6A).

The spheroid penetration ability and the cellular uptake rate could be considered as two major impact factors on the observed cytotoxicity. Hydrophobic ETO has a less efficient diffusion and can also be eliminated from cancer cells by P-glycoprotein, thus reducing the overall cytotoxic effect (38). In our experiment, the increasing dose does not improve penetration and cytotoxicity of ETO alone very efficiently compared to CHA-ETO. First, the CHA-ETO nanogel can overcome drug resistance by shielding the drug inside the carrier. Second, CHA-ETO cytotoxicity was different in cell lines that express different CD44 levels (Fig. 6B). MIA PaCa-2 cells have a high level of CD44 expression level, while MCF-7 cells express low CD44 levels, and both cell lines easily form MCS during 3D-culturing. CHA-ETO displayed 40% lower cytotoxicity in MCF-7 cells than in MIA PaCa-2 cells, and the cytotoxicity was dose-dependent in both MCS types. The CHA-ETO cytotoxicity at a constant dose (25 $\mu\text{g/mL}$) was exponentially elevated at longer incubation time in both MCS types, obviously, due to the overlapping of inner penetration in MCS and cellular accumulation of drug (Fig. 6C). CHA-ETO nanogels were more effective against MIA PaCa-2 MCS as compared to MCF-7 MCS, which is in good correlation with CD44 expression levels in these cells, but nevertheless, the overall effect on both cell types was high.

Conclusions

We developed cholesteryl-hyaluronic acid (CHA) nanogel-drug conjugates for efficient treatment of cancer cells and, especially, drug-resistant and CD44-expressing cancer cells. In the design of CHA nanogel-drug conjugates, we focused on the enhancing of various aspects of drug delivery, including drug solubility, loading capacity, nanogel size, drug release from nanogel in cytoplasm and active tumor targeting. The stronger cytotoxicity of CHA-drug nanogels in cancer cells and spheroids compared to simple HA-drug conjugates was due to better cellular uptake determined by the higher affinity of CHA nanogels to the cellular membrane and only partly by the binding with CD44 receptors overexpressed in drug-resistant cancer cells. We also demonstrated fast penetration and high therapeutic activity of CHA nanogel-drug conjugates in 3D-cultures of multicellular cancer spheroids. In conclusion, CHA nanogel-drug conjugates, as simple and effective macromolecular drugs, are suggested as promising candidates for the treatment of CD44-expressing tumors and, potentially, for eradication of CSCs in the process of overcoming resistance to chemotherapy and tumor relapse (35).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The work was supported by NIH grant R01 CA136921 (S.V.V.) and Chinese Scholarship Council (X.W.). The authors are also grateful to State Key Laboratory of Biotherapy and Cancer Center, West China Medical School, Sichuan University, China, for its support to X.W. Expert assistance of Tom Bargar (UNMC Electron Microscopy Core Facility), Victoria B. Smith (UNMC Cell Analysis Core Facility), Janice A. Taylor (UNMC Confocal Laser Scanning Microscopy Core Facility) and Ed Ezell (UNMC NMR Core Facility) is greatly appreciated.

Abbreviations

HA	hyaluronic acid
CHA	cholesteryl-HA
EBE	2,2'-(ethylenedioxy)-bis-ethylamine
DCM	dichloromethane
TEA	triethylamine
CCF	cholesteryl chloroformate
EDC	1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
HOBT	hydroxybenzotriazole
DMAP	4-Dimethylaminopyridine
DCC	N,N'-Dicyclohexylcarbodiimide
DMF	N,N-dimethylformamide
DMSO	dimethyl sulfoxide
DIPEA	N,N-Diisopropylethylamine
RhITC	Rhodamine B isothiocyanate
ETO	etoposide
SAL	salinomycin
CUR	curcumin
MTT	3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
FdU	5-fluoro-2'-deoxyuridine

References

1. Baguley BC. Multiple drug resistance mechanisms in cancer. *Mol Biotechnol.* 2010; 46:308–16. [PubMed: 20717753]
2. Jordan CT, Guzman ML, Noble M. Cancer stem cells. *N Engl J Med.* 2006; 355:1253–61. [PubMed: 16990388]
3. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. *Nat Rev Cancer.* 2012; 12:237–51. [PubMed: 22437869]
4. Crosasso P, Brusa P, Dosio F, Arpicco S, Pacchioni D, Schuber F, Cattel L. Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs. *J Pharm Sci.* 1997; 86:832–9. [PubMed: 9232525]
5. Kim S, Shi Y, Kim JY, Park K, Cheng JX. Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction. *Expert Opin Drug Deliv.* 2010; 7:49–62. [PubMed: 20017660]
6. Lu ZR, Shiah JG, Sakuma S, Kopeckova P, Kopecek J. Design of novel bioconjugates for targeted drug delivery. *J Control Release.* 2002; 78:165–73. [PubMed: 11772458]

7. Senanayake TH, Warren G, Vinogradov SV. Novel anticancer polymeric conjugates of activated nucleoside analogues. *Bioconjug Chem.* 2011; 22:1983–93. [PubMed: 21863885]
8. Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: an information-rich system. *Eur J Cell Biol.* 2006; 85:699–715. [PubMed: 16822580]
9. Prestwich GD. Hyaluronic acid-based clinical biomaterials derived for cell and molecule delivery in regenerative medicine. *J Control Release.* 2011; 155:193–9. [PubMed: 21513749]
10. Luo Y, Ziebell MR, Prestwich GD. A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. *Biomacromolecules.* 2000; 1:208–18. [PubMed: 11710102]
11. Luo Y, Bernshaw NJ, Lu ZR, Kopecek J, Prestwich GD. Targeted delivery of doxorubicin by HPMa copolymer-hyaluronan bioconjugates. *Pharm Res.* 2002; 19:396–402. [PubMed: 12033370]
12. Marhaba R, Klingbeil P, Nuebel T, Nazarenko I, Buechler MW, Zoeller M. CD44 and EpCAM: cancer-initiating cell markers. *Curr Mol Med.* 2008; 8:784–804. [PubMed: 19075676]
13. Oh EJ, Park K, Kim KS, Kim J, Yang JA, Kong JH, Lee MY, Hoffman AS, Hahn SK. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. *Journal of Controlled Release.* 2010; 141:2–12. [PubMed: 19758573]
14. Qhattal HS, Liu X. Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes. *Mol Pharm.* 2011; 8:1233–46. [PubMed: 21696190]
15. Cho HJ, Yoon HY, Koo H, Ko SH, Shim JS, Lee JH, Kim K, Kwon IC, Kim DD. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic(R) for tumor-targeted delivery of docetaxel. *Biomaterials.* 2011; 32:7181–90. [PubMed: 21733572]
16. Cho HJ, Yoon IS, Yoon HY, Koo H, Jin YJ, Ko SH, Shim JS, Kim K, Kwon IC, Kim DD. Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin. *Biomaterials.* 2012; 33:1190–200. [PubMed: 22074664]
17. Cho HJ, Yoon HY, Koo H, Ko SH, Shim JS, Cho JH, Park JH, Kim K, Kwon IC, Kim DD. Hyaluronic acid-ceramide-based optical/MR dual imaging nanoprobe for cancer diagnosis. *J Control Release.* 2012; 162:111–8. [PubMed: 22709587]
18. Boutorine A, Kostina E. Reversible covalent attachment of cholesterol to oligodeoxyribonucleotides for studies of the mechanisms of their penetration into eucaryotic cells. *Biochimie.* 1993; 75:35–41. [PubMed: 8504175]
19. Nochi T, Yuki Y, Takahashi H, Sawada S, Mejima M, Kohda T, Harada N, Kong IG, Sato A, Kataoka N, Tokuhara D, Kurokawa S, Takahashi Y, Tsukada H, Kozaki S, Akiyoshi K, Kiyono H. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. *Nat Mater.* 2010; 9:572–8. [PubMed: 20562880]
20. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. *Cell.* 2009; 138:645–59. [PubMed: 19682730]
21. Lim KJ, Bisht S, Bar EE, Maitra A, Eberhart CG. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. *Cancer Biol Ther.* 2011; 11:464–73. [PubMed: 21193839]
22. Wolny PM, Banerji S, Gounou C, Brisson AR, Day AJ, Jackson DG, Richter RP. Analysis of CD44-Hyaluronan Interactions in an Artificial Membrane System. *Journal of Biological Chemistry.* 2010; 285:30170–30180. [PubMed: 20663884]
23. Vinogradov SV, Kohli E, Zeman A, Kabanov AV. Chemical engineering of nanogel drug carriers: increased bioavailability and decreased cytotoxicity. *Polymer Prepr.* 2006; 47(2):27–28. [PubMed: 19079755]
24. Keck GE, Boden EP, Wiley MR. Total synthesis of (+)-colletodiol: new methodology for the synthesis of macrolactones. *The Journal of Organic Chemistry.* 1989; 54:896–906.
25. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. *Cancer Res.* 1995; 55:3752–6. [PubMed: 7641188]
26. Manju S, Sreenivasan K. Conjugation of curcumin onto hyaluronic acid enhances its aqueous solubility and stability. *J Colloid Interface Sci.* 2011; 359:318–25. [PubMed: 21492865]

28. Tammi R, Rilla K, Pienimäki JP, MacCallum DK, Hogg M, Luukkonen M, Hascall VC, Tammi M. Hyaluronan enters keratinocytes by a novel endocytic route for catabolism. *J Biol Chem.* 2001; 276:35111–22. [PubMed: 11451952]
29. Yang J, Chen H, Vlahov IR, Cheng JX, Low PS. Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates. *J Pharmacol Exp Ther.* 2007; 321:462–8. [PubMed: 17289839]
30. Vinogradov SV, Kohli E, Zeman AD. Cross-linked polymeric nanogel formulations of 5'-triphosphates of nucleoside analogues: role of the cellular membrane in drug release. *Mol Pharm.* 2005; 2:449–61. [PubMed: 16323952]
31. Oliferenko S, Paiha K, Harder T, Gerke V, Schwarzler C, Schwarz H, Beug H, Gunthert U, Huber LA. Analysis of CD44-containing lipid rafts: Recruitment of annexin II and stabilization by the actin cytoskeleton. *J Cell Biol.* 1999; 146:843–54. [PubMed: 10459018]
32. Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. *Science.* 1988; 240:177–84. [PubMed: 2451290]
33. Huang K, Ma H, Liu J, Huo S, Kumar A, Wei T, Zhang X, Jin S, Gan Y, Wang PC, He S, Liang XJ. Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. *ACS Nano.* 2012; 6:4483–93. [PubMed: 22540892]
34. Kim TH, Mount CW, Gombotz WR, Pun SH. The delivery of doxorubicin to 3-D multicellular spheroids and tumors in a murine xenograft model using tumor-penetrating triblock polymeric micelles. *Biomaterials.* 2010; 31:7386–7397. [PubMed: 20598741]
35. Vinogradov S, Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. *Nanomedicine (Lond).* 2012; 7:597–615. [PubMed: 22471722]
36. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. *Pharm Res.* 1996; 13:1838–1845. [PubMed: 8987081]
37. Wichitnithad W, Nimmanit U, Callery PS, Rojsitthisak P. Effects of different carboxylic ester spacers on chemical stability, release characteristics, and anticancer activity of mono-PEGylated curcumin conjugates. *J Pharm Sci.* 2011; 100(12):5206–5218. [PubMed: 21850703]
38. Leu BL, Huang JD. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. *Cancer Chemother Pharmacol.* 1995; 35(5):432–436. [PubMed: 7850926]

Figure 1. Transmission electron microscopic images of CHA nanogels: (A) CHA-ETO, (B) CHA-SAL and (C) CHA-CUR. Samples were stained with vanadate. Selected nanogel particles are shown by arrows.

Figure 2.

In vitro drug release and stability in nanogel-drug conjugates. (A) Drug release of CHA-ETO and CHA-SAL at pH 7.4, 37°C. Data are expressed as means $\pm$ SD (n=3). (B–C) Comparison of the drug stability for CHA-CUR (B) and free CUR (C) at pH 7.4, 25°C, and [CUR] = 110 μ M. The UV absorbance decrease at λ_{max} of CUR = 426 nm shows the degradation of CUR molecules.

Figure 3. Comparative cytotoxicity of CHA nanogel-drug conjugates vs. HA-drug conjugates and free drugs in MDA-MB-231/F (A, B) and MIA PaCa-2 (C) cells (MTT assay, 72 h, 37°C). Data are shown as means $\pm$ SEM (n = 8).

Figure 4. Cellular uptake of Rhodamine-labeled HA and CHA nanogels. (A) Confocal microscopy of: (a) MDA-MB-231/F cells incubated with Rh-CHA for 2 h at 37°C. (b) MDA-MB-231/F cells incubated with Rh-CHA for 2 h at 4°C. (c) MDA-MB-231/F cells pretreated with free HA and then incubated with Rh-CHA for 2 h at 37°C. (d) MDA-MB-231/F cells incubated with Rh-HA for 2 h at 37°C. (e) MCF-7 cells incubated with Rh-CHA for 2 h at 37°C. (B) CD44 expression in MDA-MB-231/F, MCF-7 and MIA PaCa-2 cells determined by flow cytometry. MFI: mean fluorescence index. (C) Quantitative comparison of the cellular uptake of fluorescent Rh-CHA measured per 50,000 cells: (a) at 4°C vs. 37°C, (b) with or without pretreatment by HA, (c) HA vs. CHA, and (d) MCF-7 vs. MDA-MB-231/F. Data are expressed as means $\pm$ SEM.

Figure 5. Penetration of Rhodamine-labeled CHA-ETO (A) and CHA-SAL (B) in MCF-7 multicellular cancer spheroids (MCS) detected by confocal microscopy (12 h, 37°C). White arrows show nanogel penetration (left: contrast image; right: fluorescent image; side length: 500 μm). (C) Schematic view of nanogel penetration into MCS and accumulation in adjacent cells.

Figure 6.

Comparative cytotoxicity of CHA-ETO, HA-ETO and ETO in MCS. (A) MIA PaCa-2 MCS (treatment 48 h, 37°C); $P < 0.05$, CHA-ETO vs. ETO, and $P < 0.05$, CHA-ETO vs. HA-ETO. (B) Dose-dependent cytotoxicity of CHA-ETO in MIA PaCa-2 and MCF-7 MCS (48 h, 37°C). (C) Time-dependent cytotoxicity of CHA-ETO in MIA PaCa-2 and MCF-7 MCS (drug concentration 25 μg/mL); $P < 0.05$, MIA PaCa-2 vs. MCF-7. Cytotoxicity was determined using LDH assay. Data are shown as means $\pm$ SEM ($n = 5$).

Scheme 1.

Synthesis of cholesteryl hyaluronic acid-drug conjugates.

Scheme 2.

Assembly of compact CHA nanogels in aqueous media and the proposed mechanism of drug delivery via nanogel binding with CD44 receptors expressed on the membrane of cancer cells, receptor-mediated endocytosis and the fusion of CHA-drug conjugates in the lipid bilayer.

Table 1

Characterization of nanogel-drug conjugates

Nanogel	Size (nm)	PDI	Drug content by weight (%)	Cholesterol content by weight (%)	Zeta potential (mV)
CHA-ETO	32.17±5.66	0.28±0.03	17.36±1.21	3.42±0.04	-31.6±2.61
CHA-SAL	36.48±6.23	0.29±0.05	21.62±1.53	3.38±0.04	-41.4±4.52
CHA-CUR	29.15±5.37	0.45±0.06	6.98±0.56	3.85±0.05	-38.4±3.89

PDI: polydispersity index. Values are mean ± standard deviation (SD) (n=3).

Table 2

Cytotoxicity of drugs and drug conjugates in cancer cells

Drug formulations	IC ₅₀ value (μM)*	Enhancement factor
Etoposide	12.3	-
HA-ETO	6.3	1.9
CHA-ETO	3	4.2
Salinomycin	5.1	-
HA-SAL	3.2	1.6
CHA-SAL	0.9	5.4
Curcumin	19	-
HA-CUR	70	0.3
CHA-CUR	9	2.1

* Cytotoxicity was measured after 72-h treatment. Enhancement factor shows the drug conjugate efficacy compared to free drug. CHA cytotoxicity (IC₅₀) was > 5 mg/mL. The data are average of eight parallel measurements. Etoposide and salinomycin conjugates were tested in MDA-MB-231/F cells; curcumin conjugates were tested in MIA PaCa-2 cells.